MicroRNA Dysregulation in Prostate Cancer.
biological network
microRNA
molecular signature
plasma
prostate adenocarcinoma
tissue
Journal
Pharmacogenomics and personalized medicine
ISSN: 1178-7066
Titre abrégé: Pharmgenomics Pers Med
Pays: New Zealand
ID NLM: 101514107
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
11
2021
accepted:
17
02
2022
entrez:
18
3
2022
pubmed:
19
3
2022
medline:
19
3
2022
Statut:
epublish
Résumé
Prostate cancer biology is complex, and needs to be deciphered. The latest evidence reveals the significant role of non-coding RNAs, particularly microRNAs (miRNAs), as key regulatory factors in cancer. Therefore, the identification of altered miRNA patterns involved in prostate cancer will allow them to be used for development of novel diagnostic and prognostic biomarkers. We performed a miRNAs transcriptomic analysis, using microarray (10 matched pairs tumor tissue versus normal adjacent tissue, selected based on inclusion criteria), followed by overlapping with TCGA data. A total of 292 miRNAs were differentially expressed, with 125 upregulated and 167 downregulated in TCGA patients' cohort with PRAD (prostate adenocarcinoma), respectively for the microarray experiments; 16 upregulated and 44 downregulated miRNAs were found in our cohort. To confirm our results obtained for tumor tissue, we performed validation with qRT-PCR at the tissue and plasma level of two selected transcripts, and finally, we focused on the identification of altered miRNAs involved in key biological processes. A common signature identified a panel of 12 upregulated and 1 downregulated miRNA, targeting and interconnected in a network with the TP53, AGO2, BIRC5 gene and EGFR as a core element. Among this signature, the overexpressed transcripts (miR-20b-5p, miR-96-5p, miR-183-5p) and the downregulated miR-542-5p were validated by qRT-PCR in an additional patients' cohort of 34 matched tumor and normal adjacent paired samples. Further, we performed the validation of the expression level for miR-20b-5p, miR-96-5p, miR-183-5p plasma, on the same patients' cohort versus a healthy control group, confirming the overexpression of these transcripts in the PRAD group, demonstrating the liquid biopsy as a potential investigational tool in prostate cancer. In this pilot study, we provide evidence on miRNA dysregulation and its association with key functional components of the PRAD landscape, where an important role is acted by miR-20b-5p, miR-542-5p, or the oncogenic cluster miR-183-96-182.
Identifiants
pubmed: 35300057
doi: 10.2147/PGPM.S348565
pii: 348565
pmc: PMC8923686
doi:
Types de publication
Journal Article
Langues
eng
Pagination
177-193Informations de copyright
© 2022 Schitcu et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in this work.
Références
Curr Genomics. 2018 May;19(4):258-278
pubmed: 29755289
Biosci Rep. 2019 May 14;39(5):
pubmed: 31015365
Clin Cancer Res. 2018 Sep 15;24(18):4551-4565
pubmed: 29844131
Oncotarget. 2018 Feb 17;9(17):13894-13910
pubmed: 29568403
Cell Rep. 2020 May 26;31(8):107669
pubmed: 32460015
Carcinogenesis. 2019 Apr 29;40(2):246-253
pubmed: 30452625
Int J Nanomedicine. 2015 Jan 20;10:791-800
pubmed: 25653521
PLoS One. 2019 Nov 22;14(11):e0224071
pubmed: 31756185
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Cancer Res. 2014 Jun 15;74(12):3218-27
pubmed: 24762395
J Exp Clin Cancer Res. 2018 Oct 20;37(1):257
pubmed: 30342533
Carcinogenesis. 2020 Jul 14;41(7):865-874
pubmed: 31738404
Lancet. 2015 Feb 26;385 Suppl 1:S15
pubmed: 26312837
J Exp Clin Cancer Res. 2019 Oct 29;38(1):433
pubmed: 31665050
J Transl Med. 2018 May 21;16(1):134
pubmed: 29784056
Oncogene. 2019 Jan;38(3):421-444
pubmed: 30120411
Front Oncol. 2020 Mar 06;10:246
pubmed: 32211317
Int J Mol Sci. 2017 Dec 05;18(12):
pubmed: 29206174
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
BMC Cancer. 2019 Feb 8;19(1):129
pubmed: 30736753
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Int J Nanomedicine. 2014 Jul 22;9:3465-79
pubmed: 25092977
Indian J Clin Biochem. 2019 Apr;34(2):207-212
pubmed: 31092995
Br J Cancer. 2015 Aug 11;113(4):611-5
pubmed: 26203762
PLoS One. 2019 Jun 19;14(6):e0218618
pubmed: 31216325
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Int J Mol Sci. 2019 May 31;20(11):
pubmed: 31151317
Aging (Albany NY). 2020 Jun 17;12(12):11500-11516
pubmed: 32554858
Clin Cancer Res. 2019 May 15;25(10):3016-3025
pubmed: 30808771
Comput Struct Biotechnol J. 2021 Aug 31;19:4941-4953
pubmed: 34527198
EMBO J. 2019 Mar 1;38(5):
pubmed: 30723117
J Hematol Oncol. 2017 Oct 26;10(1):169
pubmed: 29073933
Mol Aspects Med. 2019 Dec;70:90-105
pubmed: 31703947
Oncotarget. 2016 Apr 19;7(16):22566-78
pubmed: 26992225
Neoplasia. 2015 Aug;17(8):634-49
pubmed: 26408256
Curr Pharm Des. 2014;20(42):6565-74
pubmed: 25341933
Genome Res. 2016 Mar;26(3):331-41
pubmed: 26701625
J Biol Chem. 2011 Dec 30;286(52):44503-11
pubmed: 22045813
Int J Mol Sci. 2021 Apr 22;22(9):
pubmed: 33922033
Diagnostics (Basel). 2019 Dec 09;9(4):
pubmed: 31818027
Int J Cancer. 2014 Sep 15;135(6):1369-80
pubmed: 24523142
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4548-4556
pubmed: 29131261
J Exp Clin Cancer Res. 2019 Mar 29;38(1):141
pubmed: 30925916
Res Rep Urol. 2019 Feb 27;11:29-42
pubmed: 30881943
BMC Med Genomics. 2020 Sep 18;13(Suppl 8):129
pubmed: 32948204
Cells. 2020 Jan 23;9(2):
pubmed: 31979244
Front Oncol. 2020 Jan 15;9:1535
pubmed: 32010624
Mol Cell Biochem. 2013 Sep;381(1-2):61-8
pubmed: 23881244
Cancers (Basel). 2019 Apr 30;11(5):
pubmed: 31052265
Cancers (Basel). 2020 Mar 31;12(4):
pubmed: 32244548
Oncol Lett. 2017 Dec;14(6):6895-6900
pubmed: 29163708
RNA Biol. 2012 Jun;9(6):781-91
pubmed: 22664917
Cancers (Basel). 2021 Jan 11;13(2):
pubmed: 33440913
Int J Mol Sci. 2017 Jul 13;18(7):
pubmed: 28703782
Drug Des Devel Ther. 2020 Nov 02;14:4659-4670
pubmed: 33173276
Asian Pac J Cancer Prev. 2020 Nov 01;21(11):3365-3371
pubmed: 33247697